Trial Profile

Efficacy and Safety of Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia: A Single-arm, Open-label Phase II Study

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Baricitinib (Primary)
Indications Idiopathic thrombocytopenic purpura
Focus Therapeutic Use
Acronyms BAITP

Most Recent Events

01 Oct 2024 Status changed to completed as per results published in the American Journal of Hematology
01 Oct 2024 Results published in the American Journal of Hematology
15 Jun 2023 Results (n=35)assessing efficacy and safety of baricitinib as second-line therapy for patients with steroid-resistant or relapsed ITP, presented at the 28th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com